{
  "trial_id": "NCT03294694",
  "overall_assessment": "likely_eligible",
  "inclusion": [
    {
      "criterion": "Cohort A Dose Escalation (Ribociclib + PDR001) Eligibility can be found in Detailed Description Section",
      "label": "unknown",
      "evidence": "quote"
    },
    {
      "criterion": "ECOG Performance Status 0-1",
      "label": "met",
      "evidence": "none"
    },
    {
      "criterion": "Participants must have normal organ and marrow function, as defined below:",
      "label": "met",
      "evidence": "none"
    },
    {
      "criterion": "absolute neutrophil count \u22651,500/mcL",
      "label": "unknown",
      "evidence": "quote"
    },
    {
      "criterion": "platelets \u2265100,000/mcL",
      "label": "unknown",
      "evidence": "quote"
    },
    {
      "criterion": "total hemoglobin \u2265 9 g/dL (may be post-transfusion)",
      "label": "unknown",
      "evidence": "quote"
    },
    {
      "criterion": "total bilirubin \u22641.5 x institutional ULN (IULN)",
      "label": "met",
      "evidence": "none"
    },
    {
      "criterion": "AST(SGOT)/ALT(SGPT) \u22642.5 \u00d7 IULN or \u22645 \u00d7 IULN for participants with liver metastases",
      "label": "unknown",
      "evidence": "quote"
    },
    {
      "criterion": "creatinine \u22641.5 x IULN or \u2265 60 ml/min/1.73m2 for subjects with creatinine levels above institutional normal",
      "label": "met",
      "evidence": "none"
    },
    {
      "criterion": "INR \u2264 1.5",
      "label": "unknown",
      "evidence": "quote"
    },
    {
      "criterion": "estimated glomerular filtration rate (eGFR) \u2265 30 mL/min/1.73 by either Cockcroft-Gault or CKD-EPI",
      "label": "met",
      "evidence": "none"
    },
    {
      "criterion": "baseline QTc \u2264 450 msec",
      "label": "unknown",
      "evidence": "quote"
    },
    {
      "criterion": "Age > 18 years",
      "label": "met",
      "evidence": "none"
    }
  ],
  "exclusion": [
    {
      "criterion": "Participants cannot have been treated on a prior interventional, investigational study within 2 weeks of the first dose of study treatment.",
      "label": "not_met",
      "evidence": "quote"
    },
    {
      "criterion": "Participants cannot receive treatment with any other investigational agents during protocol therapy.",
      "label": "not_met",
      "evidence": "quote"
    },
    {
      "criterion": "Use of hematopoietic colony-stimulating growth factors (e.g. G-CSF, GMCSF, M-CSF) \u22642 weeks prior start of study drug.",
      "label": "not_met",
      "evidence": "quote"
    },
    {
      "criterion": "History of severe hypersensitivity reactions to other mAbs",
      "label": "unknown",
      "evidence": "quote"
    },
    {
      "criterion": "Participants requiring chronic treatment with systemic steroid therapy, other than replacement-dose steroids in the setting of adrenal insufficiency within 7 days of treatment initiation.",
      "label": "not_met",
      "evidence": "quote"
    }
  ],
  "notes": "The patient is a 45-year-old postmenopausal woman with cytologically confirmed breast cancer. She has a 3 cm invasive ductal breast carcinoma in the left upper outer quadrant, which is HER2-positive and ER/PR negative. Axillary sampling revealed 5 positive lymph nodes. CXR was remarkable for metastatic lesions.",
  "_meta": {
    "topic_id": "61",
    "trial_id": "NCT03294694",
    "model": "llama3.1:8b",
    "run_tag": "llama31_8b_full_top100",
    "top_k": 100
  }
}